<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40812266</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-1983</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Clinical nutrition (Edinburgh, Scotland)</Title><ISOAbbreviation>Clin Nutr</ISOAbbreviation></Journal><ArticleTitle>Effects of time-restricted eating on glycemic control in type 2 diabetes: A 12-week quasi-experimental single-arm study with 1-year follow-up.</ArticleTitle><Pagination><StartPage>263</StartPage><EndPage>274</EndPage><MedlinePgn>263-274</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clnu.2025.08.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0261-5614(25)00216-X</ELocationID><Abstract><AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">Time-restricted eating (TRE) is a newly emerging dietary strategy that reduces body weight and improves glucose tolerance in individuals with overweight or obesity. However, whether TRE is effective in improving glycemic control in individuals with diabetes remains unexplored. Herein, we aimed to investigate the effects of TRE intervention on glycemic control in patients with type 2 diabetes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this single-center, open-label, self-controlled trial, 18 overweight or obese adults with type 2 diabetes inadequately controlled on lifestyle modification alone or in combination with metformin and/or &#x3b1;-glycosidase inhibitors were enrolled to receive a 10-h TRE for 12 weeks. The effects of TRE on glucose metabolism, body weight, body composition and other metabolic parameters were evaluated in these participants following the intervention.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 12-week TRE intervention not only significantly reduced body weight (-1.72 &#xb1; 1.83 kg, P &lt; 0.001), but also remarkably improved glycemic control, with reduced glycated hemoglobin (HbA1c; -0.69 % &#xb1; 0.48 %, P &lt; 0.001) and fasting blood glucose (-0.90 &#xb1; 1.27 mmol/L, P = 0.008) levels. In addition, TRE also significantly reduced triglyceride level (-0.26 mmol/L [-0.52 to -0.04 mmol/L], P = 0.004) and fatty liver index (-8.64 [-15.4 to -2.87], P = 0.003) after 12 weeks of intervention. Notably, the benefits for HbA1c reduction lasted for up to 1 year.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">TRE can improve glycemic control up to 1 year in individuals with type 2 diabetes. Our findings indicate that TRE may represent a novel diet management option for patients with type 2 diabetes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Rongsong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jingpin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nursing Department, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Guoqiang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wenhui</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuo</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qun</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University Third Hospital, Beijing, China. Electronic address: wq3025@sina.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Tianpei</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University Third Hospital, Beijing, China. Electronic address: tpho66@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Nutr</MedlineTA><NlmUniqueID>8309603</NlmUniqueID><ISSNLinking>0261-5614</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085002" MajorTopicYN="Y">Glycemic Control</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050177" MajorTopicYN="N">Overweight</DescriptorName><QualifierName UI="Q000178" MajorTopicYN="N">diet therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015431" MajorTopicYN="N">Weight Loss</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005215" MajorTopicYN="N">Fasting</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Blood glucose</Keyword><Keyword MajorTopicYN="N">Body weight</Keyword><Keyword MajorTopicYN="N">Dietary intervention</Keyword><Keyword MajorTopicYN="N">Time-restricted eating</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword></KeywordList><CoiStatement>Conflict of interest The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>31</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>14</Day><Hour>22</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>14</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40812266</ArticleId><ArticleId IdType="doi">10.1016/j.clnu.2025.08.002</ArticleId><ArticleId IdType="pii">S0261-5614(25)00216-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>